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Abstract
Paclitaxel (Taxol)-induced cell death requires the intrinsic cell death pathway, but the specific participants and the precise
mechanisms are poorly understood. Previous studies indicate that a BH3-only protein BIM (BCL-2 Interacting Mediator of cell
death) plays a role in paclitaxel-induced apoptosis. We show here that BIM is dispensable in apoptosis with paclitaxel
treatment using bim2/2 MEFs (mouse embryonic fibroblasts), the bim2/2 mouse breast tumor model, and shRNA-mediated
down-regulation of BIM in human breast cancer cells. In contrast, both bak2/2 MEFs and human breast cancer cells in which
BAK was down-regulated by shRNA were more resistant to paclitaxel. However, paclitaxel sensitivity was not affected in
bax2/2 MEFs or in human breast cancer cells in which BAX was down-regulated, suggesting that paclitaxel-induced
apoptosis is BAK-dependent, but BAX-independent. In human breast cancer cells, paclitaxel treatment resulted in MCL-1
degradation which was prevented by a proteasome inhibitor, MG132. A Cdk inhibitor, roscovitine, blocked paclitaxel-
induced MCL-1 degradation and apoptosis, suggesting that Cdk activation at mitotic arrest could induce subsequent MCL-1
degradation in a proteasome-dependent manner. BAK was associated with MCL-1 in untreated cells and became activated
in concert with loss of MCL-1 expression and its release from the complex. Our data suggest that BAK is the mediator of
paclitaxel-induced apoptosis and could be an alternative target for overcoming paclitaxel resistance.
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Introduction
Breast cancer is a leading cause of death among women.
Understanding breast cancer at the molecular level is imperative
for finding more effective approaches to successfully treat these
patients. Microtubule inhibitors are among the most frequently
used agents for breast cancer treatment, with proven efficacy in
both localized and metastatic disease. Paclitaxel (Taxol) is a
member of the taxane class of anti-neoplastic microtubule
damaging agents and exhibits activity against a wide range of
human malignancies including breast cancer [1,2]. Paclitaxel
stabilizes microtubules, resulting in G2/M cell cycle arrest, and
continuous treatment with paclitaxel ultimately leads to cell death.
However, the precise mechanisms of how this mitotic arrest
triggers cell death are still unclear.
When cells undergo paclitaxel-induced cell death, the BCL-2
family-dependent mitochondrial apoptotic pathway is activated
[3,4]. The BCL-2 family is subdivided into three main groups
based on regions of BCL-2 homology (BH) and function: multi-
domain anti-apoptotic (BCL-2, MCL-1, BCL-XL), multidomain
pro-apoptotic (BAX, BAK), and BH3-only pro-apoptotic (for
example, BIM, BID, BAD, PUMA). The BH3-only proteins
clearly act upstream of BAX and BAK because they cannot induce
apoptosis in cells lacking both BAX and BAK. BH3-only proteins
cause cytochrome c release by activating BAX and/or BAK, and
the anti-apoptotic BCL-2 family of proteins prevents this process
[3,4]. Among the BCL-2 family cell death regulators, a BH3-only
protein BIM (Bcl-2 Interacting Mediator of cell death) has been
shown to play a role in paclitaxel-induced cell death. Down
regulation of BIM by siRNA delays paclitaxel-mediated apoptosis
in cell based models [5,6,7,8]. In addition, E1A and dominant-
negative p53 transformed BMK (baby mouse kidney) cell lines of
bim2/2 mice showed the importance of BIM expression for
paclitaxel cytotoxicity [9]. On the contrary, shRNA-mediated
BIM depletion studies demonstrate that BIM is not required for
paclitaxel cytotoxicity in breast cancer cell lines [10].
It is imperative to define the contribution of BIM in paclitaxel-
induced apoptosis in order to rationally develop enhanced
treatment strategies. Although cell culture model systems are
well-suited for biochemical questions, they are relatively contrived
with regard to factors such as substrate attachment and growth
factor availability, both of which have profound effects on cellular
susceptibility to apoptosis. For this reason, it is important to extend
the knowledge gained from cell culture settings to in vivo models
that more closely mimic the cell type, cellular environment, and
tumor evolution processes encountered in human tumors. Thus,
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we obtained the MMTV-ErbB2 line of mice, a well-established
breast cancer mouse model, and generated a breeding colony of
MMTV-ErbB2/bim2/2 mice. In addition to this mouse tumor
model, all of our in vitro and in vivo models support that BIM is
dispensable in paclitaxel-induced apoptosis. Furthermore, both
bak2/2 mouse embryonic fibroblasts (MEFs) and human breast
cancer cells in which BAK is down-regulated by shRNA are more
resistant to low doses of paclitaxel treatment. Our data suggest that
BAK is a critical mediator of paclitaxel-induced apoptosis through
its release from the complex with MCL-1.
Materials and Methods
Cell Lines and Culture
Simian virus 40 (SV40)-immortalized MEFs were kindly
provided by Dr. Stanley Korsmeyer (Dana-Farber Cancer
Institute, Boston, MA) [11,12]. All human breast cancer cells
were purchased from the American Tissue Culture Collection
(Manassas, VA). Cells were cultured in DMEM supplemented
with 10% heat-inactivated fetal bovine serum (FBS) and penicillin
G/streptomycin at 37uC in a humidified, 5% CO2 incubator.
Mice
The mice study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of Virginia Commonwealth University [Protocol
Number: AD20132 (PI: Hisashi Harada)]. MMTV-ErbB2 mice
[13] were purchased from The Jackson Laboratory (Bar Harbor,
ME). Bim2/2 mice [12] were obtained from Dr. Stanley
Korsmeyer (Dana-Farber Cancer Institute, Boston, MA). The
mice were interbred to generate cohorts of MMTV-ErbB2/bim+/+
and MMTV-ErbB2/bim2/2 female mice. The bim2/2 mice were
originally obtained in a C57BL/6 background, while the MMTV-
ErbB2 mice were obtained in an FVB background. However, they
were subsequently maintained in our laboratory in a mixed genetic
background including C57BL/6 and FVB. The presence or
absence of ErbB2 and bim alleles in offspring of the interbreedings
was determined by PCR. Genomic DNA was extracted from a
small piece of tail cut from each animal at the time of weaning.
PCR reactions were carried out as described previously [12]. In
MMTV-ErbB2 transgenic mice, mammary tumors arise primarily
in females, and the kinetics of tumor onset is significantly
accelerated by pregnancy and lactation. To avoid the complicating
effects of pregnancy on tumorigenesis, we maintained all
experimental females as virgins. Tumor volume in mm3 was
estimated using the formula: vol = (L x W2)/2, where L is the
larger dimension and W is the smaller dimension in millimeter
with caliper measurement. Tumor growth was monitored from the
time of initial tumor detection until the tumor reached a size of
,500 mm3. The mice then began receiving paclitaxel treatment
(15 mg/kg) by intra-peritoneal injection daily for 9 days [14].
Tumor size was measured every other day to determine tumor
growth response to paclitaxel. The measurement used in the
analysis was based on the area under the tumor growth curve
(AUC). The AUC is determined by numerical methods for each
mouse, and is then normalized over time to give an AUC/day,
which is referred to as the mean growth rate (MGR). The MGR
values for all mice in a treatment group were averaged to provide
the mean MGR for that group, along with the standard error of
the mean. Tumor growth was also measured in vehicle-treated
mice per genotype for 9 days after their tumor reached a size of
,500 mm3.
Culture of Primary Mouse Mammary Epithelial Cells
The protocol was approved by the Institutional Animal Care
and Use Committee of Virginia Commonwealth University
[Protocol Number: AD20132 (PI: Hisashi Harada)]. A size of
,500 mm3 tumors was mechanically processed, dissociated in
collagenase/dispase (Roche, Indianapolis, IN) for 2 hours at 37uC,
washed with PBS +1 mM EDTA and cultured in DMEM
supplemented with 2% FBS and Mammary Epithelial Growth
Supplement (MEGS) (Invitrogen, Carlsbad, CA) at 37uC in a
humidified, 5% CO2 incubator.
Chemicals and Antibodies
Paclitaxel was purchased from Sigma (St. Louis, MO) for cell
culture studies and from SAGENT Pharmaceuticals (Schaumburg,
IL) for the animal study. Roscovitine and MG132 were purchased
from Sigma and Millipore (Billerica, MA), respectively. Antibodies
were purchased as follows: BIM, BCL-XL, Cleaved PARP,
Cleaved Caspase-3, and ErbB2 from Cell Signaling Technology
(Beverly, MA); mouse MCL-1 from Rockland Immunochemicals
(Gilbertsville, PA); human MCL-1 from Enzo Life Sciences
(Farmingdale, NY); BAX, Cyclin B1, Histone H1, a-Tubulin,
and normal rabbit IgG from Santa Cruz Biotechnology (Santa
Cruz, CA); BAK (06–536), BAK (Ab-1), and phospho-Histone H1
from Millipore.
Plasmid Transfection and Lentivirus Infection
The lentiviral short-hairpin RNA (shRNA)-expressing con-
structs were purchased from Open Biosystems (Huntsville, AL).
The constructs were transfected into 293T packaging cells along
with the packaging plasmids, and the lentivirus-containing
supernatants were used to transduce human breast cancer cells.
Cell Death Assay
Cell death was quantified by the amount of DNA fragmentation
using the Cell Death Detection ELISAplus kit (Roche) according to
the manufacturer’s protocol, or the cell numbers determined by
trypan-blue exclusion.
Immunoprecipitation and Western Blot Analyses
Whole cell lysates were prepared with CHAPS lysis buffer
[20 mM Tris (pH 7.4), 137 mM NaCl, 1 mM dithiothreitol
(DTT), 1% CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-
1-propanesulfonate), a protease inhibitor cocktail, and phospha-
tase inhibitor cocktails (Sigma)]. For immunoprecipitation, equal
amounts of protein were precleared with protein A/G beads
(Pierce, Rockford, IL), and incubated with the appropriate
antibodies on ice for 2 hours. Then the antibody complexes were
captured with protein A/G beads at 4uC for 1 hour. After washing
three times with the same lysis buffer, the beads were re-suspended
in the sample buffer and separated by SDS-PAGE. For Western
blot analyses, equal amounts of proteins were loaded on a SDS-
acrylamide gel, transferred to a nitrocellulose membrane and
analyzed by immunoblotting. Phosphorylated MCL-1 was detect-
ed on 10% SDS-PAGE with 25 mM Phos-tag acrylamide (Wako,
Richmond, VA) according to the manufacturer’s protocol [15].
Statistical Analysis
Values represent the means 6 SD for three separate exper-
iments. The significance of differences between experimental
variables was determined using the Student’s t test. Values were
considered statistically significant at P,0.05.
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Results
BIM is Dispensable for Paclitaxel-induced Apoptosis in
both in vitro and in vivo
In order to examine the role of BIM in paclitaxel-induced cell
death, we prepared mouse embryonic fibroblasts (MEFs) from
wild-type and bim2/2 mice and treated with 20 nM of paclitaxel
for 48 hrs. Free nucleosomal DNA, indicative of DNA cleavage
followed by apoptotic cell death, was observed in both wild-type
and bim2/2 MEFs (Figure 1A). Cleaved-PARP was also detected
at 24 hours after the treatment and increased at 48 hours in both
wild-type and bim2/2 MEFs (Figure 1B). In contrast, both DNA
cleavage and cleaved PARP was undetectable in bax2/2bak2/2
(dKO) MEFs, consistent with the previous observations. BIM was
induced over the time period in both wild-type and dKO MEFs,
suggesting that BIM may receive a signal(s) of mitotic checkpoint.
These results suggest that paclitaxel-induced cell death depends on
BAX and/or BAK mediated mitochondrial apoptotic pathway,
but is independent of BIM.
To further investigate whether paclitaxel could induce BIM-
independent celldeath,weestablishedan in vivo bim2/2mousebreast
tumor model. ErbB2 (HER2, neu) is a proto-oncogene that belongs to
the epidermal growth factor receptor (EGFR) family [16,17]. ErbB2
is frequently (,30%) overexpressed in breast tumors [18]. MMTV-
ErbB2 transgenicmiceproduce spontaneousbreast tumorswithin6–
8months of average tumor onset [13]. To generateMMTV-ErbB2/
bim2/2 mice, bim2/2 mice were interbred to MMTV-ErbB2
transgenic mice. The MMTV-ErbB2 female mice with bim+/+,
bim+/2, and bim2/2 were born with the numbers of 86:76:28,
suggesting that BIM contributes to the development of mice.
However, tumor onset was 6–8 months in average regardless of the
bim status. As we previously established the treatment protocol [14],
tumor-bearing mice were treated with 15 mg/kg of paclitaxel for 9
consecutive days. Without the treatment, tumors in both bim+/+ and
bim2/2 mice grew with MGR=23.5%/day for bim+/+ and
MGR=12.0%/day for bim2/2, respectively, suggesting that BIM
plays a role in ErbB2-mediated tumor growth. With paclitaxel
treatment, tumors in both genotypes shrink in similar ratio
(MGR=25.2%/day) (Figure 2). We further confirmed BIM-
independent cell death induced by paclitaxel in breast tumors ex vivo.
Treatment with paclitaxel in mouse mammary epithelial cells from
both bim+/+ and bim2/2 induced apoptosis to a similar extent
(Figure 3A). BIM was clearly induced in bim+/+ cells as similarly
observed in MEFs, suggesting that a signal(s) of mitotic checkpoint
was transduced (Figure 3B). Taken together, all experiments in
in vitro, in vivoand ex vivo indicate thatBIMisdispensable inpaclitaxel-
induced apoptosis.
Paclitaxel-induced Apoptosis is BAK-dependent
Since bax2/2bak2/2 MEFs were resistant to paclitaxel-induced
cell death (Figure 1), we next examined whether BAX and/or
BAK were required for the cell death. We took advantage of using
bax2/2 and bak2/2 MEFs with paclitaxel treatment. Bax2/2
MEFs showed similar amounts of apoptosis with wild-type MEFs,
judged by DNA fragmentation and PARP cleavage (Figure 4A and
4B). In contrast, bak2/2 MEFs were resistant to apoptosis induced
by paclitaxel treatment to a similar extent as dKO MEFs. These
results suggest that BAK plays a crucial role in paclitaxel-induced
apoptosis and BAX is redundant.
In order to examine the role of BAK in paclitaxel-sensitivity in
human breast cancer cell lines, we determined the levels of BAK in
five human breast cancer cell lines. Among the cell lines we
examined, SK-BR-3 showed the highest and T47-D showed the
lowest BAK expression (Figure S1A). In accordance with BAK
expression, SK-BR-3 was more sensitive to paclitaxel than T47D,
implicating that the level of BAK could determine the paclitaxel
sensitivity (Figure S1B). We then examined whether BAK played a
role in paclitaxel-induced apoptosis. Down-regulation of BAK by
shRNA in both SK-BR-3 and T47-D inhibited PARP cleavage,
indicative of apoptosis (Figure 5). The levels of MCL-1 were
gradually decreased with paclitaxel treatment in both control cells
Figure 1. BIM is dispensable for paclitaxel-induced apoptosis in MEFs. (A) MEFs were treated with 50 nM of paclitaxel for 48 hrs. Cell death
was determined by DNA fragmentation using the Cell Death Detection ELISAplus kit (Roche). Average values from triplicate samples are shown as
representative of two independent experiments. (B) MEFs were treated with 50 nM of paclitaxel for the indicated times. Total cell extracts were
subjected to Western blotting with the indicated antibodies.
doi:10.1371/journal.pone.0060685.g001
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and the cells in which BAK was down-regulated by shRNA. We
further established SK-BR-3 cells in which BAX or BIM was
down-regulated by shRNAs (Figure 6). In contrast with BAK
down-regulation, BAX or BIM down-regulation did not change
paclitaxel sensitivity. Similar results were also observed in MDA-
MB-468 cells in which BAK or BIM was down-regulated by
shRNA (Figure S2). Treatment with paclitaxel induced Cyclin B1,
indicative of G2/M arrest, and the decrease of MCL-1 in control
and all shRNA-transfected SK-BR-3 cells (Figure 6), suggesting
that the decrease of MCL-1 is not the consequence of cell death
[19]. Taken together, BAK plays a critical role in paclitaxel-
induced apoptosis in human breast tumor cells.
BAK is Activated with Paclitaxel Treatment by the Release
from the BAK/MCL-1 Complex
BAK is known to bind MCL-1 and BCL-XL, the anti-apoptotic
BCL-2 family proteins, before cell death signals are transduced.
Upon death stimuli, BAK is released and is activated to induce
downstream cell death pathways [20]. Immunoprecipitation
experiments with SK-BR-3 confirmed that BAK interacted with
MCL-1 and BCL-XL before paclitaxel treatment (Figure 7A).
After the treatment, the level of BAK was unchanged and the level
of MCL-1 was decreased. Accordingly, BAK/MCL-1 interaction
was decreased (Figure 7A, upper panel). In contrast, the level of
BCL-XL and BAK/BCL-XL interaction were not altered
(Figure 7A, upper panel). A reciprocal immunoprecipitation
experiment with the BCL-XL antibody confirmed BAK/BCL-
XL interaction was not altered (Figure 7A, lower panel). Decrease
of BAK/MCL-1 interaction led to the activation of BAK, judged
by the increase of BAK conformational change (Figure 7B). These
results indicate that BAK is released from the BAK/MCL-1
complex with paclitaxel treatment by the decrease of MCL-1
protein level, followed by the activation of BAK and apoptosis.
It has been shown that the degradation of MCL-1 with
microtubule damaging agents such as paclitaxel and vinblastine is
mediated through its phosphorylation by Cdk1 followed by
proteasome-dependent degradation [21,22]. When SK-BR-3 cells
were co-treated with paclitaxel and a proteosome inhibitor
MG132, MCL-1 expression was increased (Figure 7C). MCL-1
expression was also increased in cells treated with MG132 alone,
consistent with reports showing that it is normally subject to rapid
turnover via proteosome-mediated degradation in untreated cells
[23]. With the condition we used, treatment of MG132 for 24 hrs
by itself induced apoptosis, and combination with paclitaxel and
MG132 increased apoptosis presumably through the MCL-1-
independent mechanisms. It has also been reported that the
combination with paclitaxel and MG132 synergistically induces
apoptosis in breast cancer cells [24,25]. Our result suggests that
loss of MCL-1 is due to proteosome-mediated degradation. The
Cdk inhibitor roscovitine blocked paclitaxel-induced histone H1
phosphorylation (a substrate for Cdk1), MCL-1 phosphorylation,
and the decrease of intact MCL-1 protein (Figure 7D). This result
Figure 2. Mammary tumor growth response to paclitaxel in MMTV-ErbB2/Bim+/+ and MMTV-ErbB2/Bim2/2 mice. Tumor growth curves
for untreated and treated mammary tumors arising MMTV-ErbB2/Bim+/+ and MMTV-ErbB2/Bim2/2 mice are shown. Tumor-bearing mice were treated
nine consecutive days with paclitaxel (15 mg/kg) and tumor growth was monitored by caliper measurements. Each line represents the growth of an
individual tumor.
doi:10.1371/journal.pone.0060685.g002
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suggests that Cdk1 mediated phosphorylation of MCL-1 triggers
the degradation. As a consequence of inhibition of MCL-1
degradation, more BAK/MCL-1 complex was detected by co-
immunoprecipitation with anti-BAK, and cells showed less
apoptosis induced with paclitaxel treatment judged by the amount
of cleaved PARP (Figure 7D and 7E). The inhibition of MCL-1
degradation by MG132 or roscovitine was also observed in MDA-
MB468 or T47-D cells (Figure S3). Taken together, the results
Figure 3. BIM is dispensable for paclitaxel-induced apoptosis in ex vivo mouse mammary tumors. (A) Mouse mammary epithelial cells
were treated with 1 mM of paclitaxel for 48 hrs. Cell death was determined by DNA fragmentation using the Cell Death Detection ELISAplus kit
(Roche). Average values from triplicate samples are shown as representative of two independent experiments. (B) Mouse mammary epithelial cells
were treated with 1 mM of paclitaxel for the indicated time. Total cell extracts were subjected to Western blotting with the indicated antibodies.
doi:10.1371/journal.pone.0060685.g003
Figure 4. BAK plays a role in paclitaxel-induced apoptosis in MEFs. (A) MEFs were treated with 50 nM of paclitaxel for 48 hrs. Cell death was
determined by DNA fragmentation using the Cell Death Detection ELISAplus kit. Average values from triplicate samples are shown as representative of
two independent experiments. (B) MEFs were treated with 50 nM of paclitaxel for the indicated times. Total cell extracts were subjected to Western
blotting with the indicated antibodies.
doi:10.1371/journal.pone.0060685.g004
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Figure 5. BAK plays a role in paclitaxel-induced apoptosis in human breast cancer cells. SK-BR-3 and T47D cells were infected with
lentiviruses expressing shRNAs for non-targeting control or BAK. Puromycin-resistant cells were pooled after each infection. Cells were treated with
20 nM paclitaxel for SK-BR-3 or 50 nM for T47-D for the indicated times and equal amounts of total cell extracts were subjected to Western blotting
with the indicated antibodies.
doi:10.1371/journal.pone.0060685.g005
Figure 6. BAK, but neither BAX nor BIM, plays a role in paclitaxel-induced apoptosis in human breast cancer cells. SK-BR-3 cells were
infected with lentiviruses expressing shRNAs for non-targeting control, BAK, BAX, or BIM. Puromycin-resistant cells were pooled after each infection.
Cells were treated with 20 nM paclitaxel for 24 hours and equal amounts of total cell extracts were subjected to Western blotting with the indicated
antibodies.
doi:10.1371/journal.pone.0060685.g006
Paclitaxel Induces BAK-Dependent Apoptosis
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e60685
indicate that BAK is activated with paclitaxel treatment by the
release from the BAK/MCL-1 complex via Cdk1-mediated
phosphorylation of MCL-1 followed by proteasome-dependent
MCL-1 degradation.
Discussion
Paclitaxel, the prototypic member of taxanes, is used in the
treatment of breast, ovarian, and lung cancers [1,2]. This
chemotherapeutic drug causes mitotic arrest, however precisely
how this mitotic arrest triggers subsequent cell death (apoptosis) is
still unclear. Several reports have demonstrated a paclitaxel-
mediated dependence on BIM, a BH3-only pro-apoptotic BCL-2
family protein [5,6,7,8,9]. On the other hand, it has been recently
reported that depletion of BIM does not impart paclitaxel
resistance to HeLa cells or breast carcinoma cell lines MCF-7,
SK-BR-3, and MDA-MB-468 [10]. Thus, more studies need to be
undertaken in order to reconcile the previously characterized role
of BIM in paclitaxel-induced cell death in mouse models and in
clinically relevant cells such as human breast cancer cells.
We therefore examined the role of BIM in paclitaxel-induced
cell death in a variety of experimental systems in in vitro and in vivo;
bim2/2 MEFs (Figure 1), the bim2/2 mouse breast tumor model
(Figure 2 and 3), and shRNA-mediated down-regulation of BIM in
human breast cancer cells (Figure 6). In the systems we have
examined, we conclude that BIM is dispensable in apoptosis with
paclitaxel treatment. At this moment, the reasons of the
discrepancy are unclear between our results and previous
observations from others.Of note, the concentrations of paclitaxel
used in Czernick et al. [10] and Zhou et al. [26] are relatively low
(20–50 nM). We carefully determined the concentrations used to
examine minimal toxicity for each cell type (20 nM for SK-BR-3
and MDA-MB-468; 50 nM for MEFs and T47D). It is well known
that paclitaxel exerts its mitotic effects by alternate mechanisms,
depending on the concentration of the drug utilized [1]. Thus, it is
possible that the mechanisms of paclitaxel-induced cell death are
also concentration-dependent.
Bim-deficient tumors grew slower than the wild-type tumors
(Figure 2), suggesting that BIM plays a role in ErbB2-mediated
tumor growth. It has been reported that BIM deficiency promotes
the development of B cell lymphomas in Em-myc transgenic mice
and tumorigenesis of E1A and dominant-negative p53 trans-
formed BMK (baby mouse kidney) cells in nude mice [9,27].
Therefore, the role of BIM in tumorigenesis may be context-
dependent. One different point between our study and others
could be p53-dependency in tumor development. Whereas the
p19Arf/p53 pathway is frequently mutated in tumors arising in
Figure 7. BAK is activated with paclitaxel treatment by the release from the BAK/MCL-1 complex. (A) SK-BR-3 cells were treated with
20 nM paclitaxel for 24 hours. Immunoprecipitations with the total cell extracts were carried out with an anti-BAK, rabbit IgG (Control) (Upper panel)
or an anti-BCL-XL antibody (Lower panel). Western blotting was carried out on precipitated samples with the indicated antibodies. (B) The SK-BR-3
total cell extracts in (A) were subjected to immunoprecipitations with a BAK (Ab-1) conformational change-specific antibody. Western blotting was
carried out on precipitated samples with an anti-BAK antibody. (C) SK-BR-3 cells were pre-treated with 5 mM MG132 for 30 minutes, and were then
treated with 20 nM paclitaxel for 24 hours. Total cell extracts were subjected to Western blotting with the indicated antibodies. (D) SK-BR-3 cells were
pre-treated with 10 mM roscovitine for 30 minutes, and were then treated with 20 nM paclitaxel for 24 hours. Total cell extracts were subjected to
Western blotting with the indicated antibodies. (E) Immunoprecipitations with the total cell extracts from (D) were carried out with an anti-BAK
antibody. Western blotting was carried out on precipitated samples with the indicated antibodies.
doi:10.1371/journal.pone.0060685.g007
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Bim+/+ Em-myc mice, it is unaffected in most Bim-deficient tumors,
indicating that BIM reduction is an effective alternative to loss of
p53 function [27]. Since the BMK cells are transformed with
genes that disrupt the RB and p53 pathways, BIM controls a
checkpoint independent of those major routes to tumorigenesis
[9]. In contrast, ErbB2-mediated tumorigenesis is controlled by
cell cycle regulators including p53 [28]. Obviously, further studies
are required to clarify these issues.
Since bax2/2/bak2/2 MEFs are insensitive to paclitaxel
treatment, we examined the possible independent role of BAX
or BAK. Not only bak2/2 MEFs, but also down-regulation of
BAK in several human breast cancer cells showed paclitaxel
resistance (Figure 4, 5, 6, and S2). Consistent with our observation,
it has been shown that down-regulation of BAK in MDA-MB-435
and MDA-MB-231 human breast cancer cell lines suppress
paclitaxel-induced apoptosis [26]. In contrast, bax2/2 MEFs or
down-regulation of BAX in breast cancer cells showed similar
paclitaxel sensitivity as wild-type MEF or control cells, respectively
(Figure 4 and 6). The roles of BAX and BAK can be redundant or
non-redundant, depending on the apoptotic stimuli. BAK plays an
essential role for apoptosis induced by Semliki Forest virus,
gliotoxin, BCL-XS, inhibitors of protein synthesis (Pseudomonas
exotoxin A, cycloheximide, ricin), and vinblastine
[22,29,30,31,32]. Among them, vinblastine belongs to mictotubule
damaging agents as paclitaxel, thus these agents could induce a
common mechanism(s) to execute apoptosis. We examined BAX
conformational change by a conformation specific antibody (6A7).
We found that BAX conformation was also changed by paclitaxel
treatment (data not shown). However, our data clearly demon-
strate that paclitaxel-induced apoptosis is BAX-independent.
There are several controversial reports about the role of BAX in
paclitaxel or vinblastine treatment [33,34,35]. Thus, more study
will be required to determine the significance of BAX conforma-
tional change with paclitaxel treatment.
Our work defines a rational mechanism whereby loss of MCL-1
leads to apoptosis in human cells. We showed that in untreated
cells BAK was bound to MCL-1. BAK/MCL-1 interaction was
decreased and BAK was released with paclitaxel treatment in
concert with loss of MCL-1 expression. BAK underwent
conformational changes recognized by an active BAK antibody
in response to paclitaxel treatment. Co-treatment with paclitaxel
and MG132 inhibited the decrease of MCL-1 expression. Thus,
proteasome-dependent MCL-1 degradation during mitotic arrest
leads to loss of sequestration of BAK permitting BAK activation
and apoptosis. We performed knockdown of MCL-1 expression in
SK-BR3 and MDA-MB468 cells. Both cell lines started to die
within 24 hours without any treatment. The induction of apoptosis
by knockdown of MCL-1 expression in SK-BR-3 cells has been
previously reported [36]. These observations are consistent with
our idea that MCL-1 degradation during mitotic arrest leads to
loss of sequestration of BAK permitting BAK activation and
apoptosis. In contrast, the level of BCL-XL was not changed and
BAK/BCL-XL interaction was not altered. Our study indicates
that MCL-1 degradation may elicit apoptosis after paclitaxel
treatment via BAK released from suppressed complexes, whereas
BCL-XL is unaffected. In contrast to the observation in human
breast tumor cells, we could not detect MCL-1 degradation upon
paclitaxel treatment in MEFs and mouse mammary epithelial
cells. Human and mouse MCL-1 are highly conserved although
several stretches of amino acids are diverged (Figure S4).
Treatment with roscovitine prevented paclitaxel-induced MCL-1
degradation, suggesting the contribution of Cdk1. Putative Cdk1
phosphorylation sites in human MCL-1, Ser64 and Thr92 [37,38]
do not exist in mouse MCL-1. Thus, the mechanisms of BAK
activation with paclitaxel treatment might be different in between
human and mouse cells.
We show that BAK plays an important role in paclitaxel
sensitivity of breast cancer cells. BAK can be a prognostic marker
to determine paclitaxel sensitivity of breast cancer patients. BAK
may potentially serve as a therapeutic target for overcoming
paclitaxel resistance in human breast cancer. These novel findings
have important implications in the development of targeted
therapeutics for overcoming paclitaxel resistance in human breast
cancer.
Supporting Information
Figure S1 The level of BAK expression and paclitaxel
sensitivity in human breast cancer cells. (A) Total cell
extracts of the indicated human breast cancer cells were subjected
to Western blotting with BAK or tubulin antibodies. (B) SK-BR-3
cells and T47-D cells were treated with the indicated concentra-
tions of paclitaxel for 48 hours. Cell death was determined by
trypan-blue exclusion. Average values from triplicate samples are
shown.
(TIF)
Figure S2 BAK, but not BIM, plays a role in paclitaxel-
induced apoptosis in human breast cancer cells. MDA-
MB-468 cells were infected with lentiviruses expressing shRNAs
for non-targeting control, BAK or BIM. Puromycin-resistant cells
were pooled after each infection. Cells were treated with 20 nM
paclitaxel for 24 hours and equal amounts of total cell extracts
were subjected to Western blotting with the indicated antibodies.
(TIF)
Figure S3 Paclitaxel-induced MCL-1 degradation was
blocked by a proteasome inhibitor MG132 or a Cdk
inhibitor roscovitine in MDA-MB468 and T47-D cells. (A)
MDA-MB468 cells were pre-treated with 5 mM MG132 for 30
minutes, and were then treated with 20 nM paclitaxel for 24
hours. Total cell extracts were subjected to Western blotting with
the indicated antibodies. (B) MDA-MB468 and T47-D cells were
pre-treated with 10 mM roscovitine for 30 minutes. MDA-MB468
cells were then treated with 20 nM paclitaxel for 24 hours and
T47-D cells were treated with 50 nM paclitaxel for 48 hours.
Total cell extracts were subjected to Western blotting with the
indicated antibodies.
(TIF)
Figure S4 Comparison of amino acid sequences be-
tween human and mouse MCL-1. Alignment of the primary
amino acids sequence of human and mouse MCL-1 is shown. The
middle line indicates the same amino acids between the
species.+indicates an amino acid similarity. Ser64 and Thr92 in
human MCL-1 are indicated with bold-italic.
(TIFF)
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